Agile Therapeutics (AGRX) Stock Price, News & Analysis

Company Overview

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Key Stats

• Today's Range: $1.51 to $1.52
• 50-Day Range: $1.43 to $1.51
• 52-Week Range: $0.20 to $2.63
• Volume: 120,900 shs
• Average Volume: 352,864 shs
• Market Capitalization: $10.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Agile Therapeutics Stock Analysis - MarketRank™

Agile Therapeutics scored higher than 3% of companies evaluated by MarketBeat, and ranked 949th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Agile Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Agile Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Agile Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AGRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Agile Therapeutics does not currently pay a dividend.

Dividend Growth

Agile Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.59

Short Interest

There is no current short interest data available for AGRX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Agile Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Agile Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.50% of the stock of Agile Therapeutics is held by insiders.

Percentage Held by Institutions

Only 10.92% of the stock of Agile Therapeutics is held by institutions.

AGRX Stock Analysis - Frequently Asked Questions

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its quarterly earnings data on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) EPS for the quarter, beating the consensus estimate of ($7.60) by $0.40. The specialty pharmaceutical company earned $1.29 million during the quarter, compared to the consensus estimate of $1.49 million.

When did Agile Therapeutics' stock split?

Agile Therapeutics shares reverse split on the morning of Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Agile Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AGRX
• CUSIP: N/A
• CIK: 1261249
• Web: www.agiletherapeutics.com
• Phone: (609) 683-1880
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,470,000.00
• Net Margins: -36.24%
• Pretax Margin: -36.24%
• Return on Equity: N/A
• Return on Assets: -147.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.56
• Quick Ratio: 0.38

Sales & Book Value

• Annual Sales: $19.98 million
• Price / Sales: 0.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.51) per share
• Price / Book: -0.27

Miscellaneous

• Outstanding Shares: 6,856,000
• Free Float: 6,822,000
• Market Cap: $10.35 million
• Optionable: Not Optionable
• Beta: 1.58